Evidence map›Paper›PMID 40004032›Full record

ReviewInternational journal of molecular sciences2025

Chronic Kidney Disease and Osteoarthritis: Current Understanding and Future Research Directions.

Rong-Sen Yang, Ding-Cheng Chan, Yao-Pang Chung, Shing-Hwa Liu

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rong-Sen YangDepartment of Orthopedics, College of Medicine and Hospital, National Taiwan University, Taipei 100, Taiwan.ORCID 0000-0002-0553-4779
Ding-Cheng ChanDepartment of Geriatrics and Gerontology, College of Medicine and Hospital, National Taiwan University, Taipei 100, Taiwan.
Yao-Pang ChungInstitute of Toxicology, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
Shing-Hwa LiuInstitute of Toxicology, College of Medicine, National Taiwan University, Taipei 100, Taiwan.ORCID 0000-0002-9976-1197

Funding

National Science and Technology Council, Taiwan NSTC 113-2314-B-002-217
6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a significant public health concern. Osteoarthritis (OA), a common form of arthritis, has been shown to have a dramatically increased prevalence, particularly among individuals aged 40-50 and older, in the presence of CKD. Furthermore, CKD may exacerbate the progression and impact of OA. A survey study revealed that 53.9% of CKD patients undergoing long-term hemodialysis were diagnosed with OA. These findings underscore the potential association between CKD and OA. Uremic toxins, such as indoxyl sulfate, p-cresyl sulfate, transforming growth factor-β, and advanced glycation end-products, are regarded as potential risk factors in various CKD-related conditions, affecting bone and joint metabolism. However, whether these factors serve as a bridging mechanism between CKD and OA comorbidities, as well as their detailed roles in this context, remains unclear. Addressing the progression of OA in CKD patients and identifying effective treatment and prevention strategies is an urgent challenge that warrants immediate attention. This review focuses on describing and discussing the molecular pathological mechanisms underlying CKD-associated OA and the possible therapeutic strategies.

Indexed as

OsteoarthritisRenal Insufficiency, ChronicAnimalsDisease ProgressionGlycation End Products, AdvancedHumansRisk FactorsUremic ToxinsGlycation End Products, AdvancedUremic Toxinscalciumchronic kidney diseaseironosteoarthritisuremic toxins

Identifiers

PMID40004032
PMCPMC11854965

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.